Inoue et al. classified AOSD patients into two groups based on serum IL-6 and IL-18 levels; indeed, while sJIA/AOSD patients exhibiting higher IL-6 levels presented with prevalent articular manifestations, those with IL-18 dominant patterns had a more severe systemic disease and developed MAS. The gene discussed is IL6; the disease is macrophage activation syndrome.